- Research Article
- Open Access
Plasma Fibrinogen Is a Natural Deterrent to Amyloid β-Induced Platelet Activation and Neuronal Toxicity
Molecular Medicine volume 22, pages 224–232 (2016)
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, characterized by extensive loss of neurons and deposition of amyloid β (Aβ) in the form of extracellular plaques. Aβ is considered to have a critical role in synaptic loss and neuronal death underlying cognitive decline. Platelets contribute to 95% of circulating amyloid precursor protein that releases Aβ into circulation. We have recently demonstrated that the Aβ active fragment containing amino acid sequence 25–35 (Aβ25–35) is highly thrombogenic in nature and elicits strong aggregation of washed human platelets in a RhoA-dependent manner. In this study, we evaluated the influence of fibrinogen on Aβ-induced platelet activation. Intriguingly, Aβ failed to induce aggregation of platelets suspended in plasma but not in buffer. Fibrinogen brought about dose-dependent decline in aggregatory response of washed human platelets elicited by Aβ25–35, which could be reversed by increasing doses of Aβ. Fibrinogen also attenuated Aβ-induced platelet responses such as secretion, clot retraction, rise in cytosolic Ca+2 and reactive oxygen species. Fibrinogen prevented intracellular accumulation of full-length Aβ peptide (Aβ42) in platelets as well as neuronal cells. We conclude that fibrinogen serves as a physiological check against the adverse effects of Aβ by preventing its interaction with cells.
Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting the elderly and is characterized by progressive decline in cognitive faculties, particularly memory. The two pathognomonic features of this condition are extracellular senile plaques and intracellular neurofibrillary tangles (1), which are composed of fibrillar amyloid β (Aβ) aggregates (2) and hyperphosphorylated Tau proteins (3), respectively. The precise molecular pathogenesis of AD remains to be elucidated (4). However, there is growing evidence for the “amyloid hypothesis” (5), where Aβ is considered pivotal to synaptic loss and neuronal death underlying cognitive decline (6). Several possible mechanisms of Aβ-induced neurotoxicity have been recognized, including mitochondrial dysfunction (7), abnormal calcium homeostasis (8,9), oxidative stress (10), excitotoxicity (11), upregulation of proapoptotic proteins (12,13) and inactivation of growth promoting signaling pathways (13–15).
Aβ peptide ending at residue 40 (Aβ40) also deposits in cerebral vessel walls, leading to cerebral amyloid angiopathy (CAA) (16), an invariable presenting feature of AD (17). Aβ induces apoptosis of vascular endothelial (18) as well as smooth muscle cells (19). Thus, cerebrovascular dysfunction is an early event in pathogenesis of AD (20). Aβ is reported to have multiple binding partners (21), such as receptors for glutamate (22), acetylcholine (23) and nerve growth factor (24), cellular prion protein (25) and Frizzled (15), several of which play critical role in the pathophysiology of AD. However, the influence of these interactions on Aβ toxicity as well as their potential for therapeutic exploitation has not yet been fully explored.
We have recently demonstrated that the active fragment of Aβ elicits strong aggregation of washed human platelets, which was associated with exocytosis of platelet granule contents, activation of surface membrane integrins and spreading of platelets on immobilized matrix, all mediated through RhoA-dependent actomyosin reorganization (26). There have been reports of interaction between amyloid peptide and fibrin clots through binding site located near the C terminus of the fibrinogen β-chain (27), which makes the clot resistant to proteolytic degradation (28–30). These observations present compelling evidence in support of prothrombotic attributes of Aβ. In this study, we demonstrate that fibrinogen is a potent attenuator of Aβ-induced platelet activation in blood and thus serves as physiological deterrent to adverse vascular effects of Aβ.
Materials and Methods
Aβ25–35 (GSNKGAIIGLM), apyrase, ethylene glycol tetraacetic acid, ethylene-diaminetetraacetic acid (EDTA), aspirin, thrombin, fibrinogen (plasminogen-free), bovine serum albumin (BSA) and minimum essential medium (MEM) nonessential amino acids solution (100×) were purchased from Sigma. Fluorescence-activated cell sorting (FACS) flow sheath fluid and anti-CD62P antibodies were from BD Biosciences. Collagen and Chronolume luciferin-luciferase reagent were procured from Chrono-log. Aβ25–35 Aβ1–42 and Hylite-555 fluor-labeled Aβ42 were purchased from Anaspec. Aβ1–40 solution was a kind gift from Prof. Jay Kant Yadav, Central University of Rajasthan, India. DMEM/F12 (Dulbecco’s modified Eagle medium) was procured from Cell Clone; heat-inactivated fetal bovine serum and antibiotic-antimycotic solutions (100×) were obtained from Gibco. Antibodies against β-actin and phosphorylated myosin light chain phosphatase (MYPT1) were from Sigma and Cell Signaling Technology, respectively. All other reagents were of analytical grade. Type I deionized water (18.2 M Ω ·cm, Millipore) has been used throughout the experiments.
Preparation of Aβ Solution
Working stock (1 mmol/L) of Aβ25–35 was prepared in distilled water and stored at −20°C in aliquots. The solution was incubated at 25°C for 4 h before the experiments. Aβ1-42 (1 mg/mL) was prepared by adding 70–80 µL of 1% NH4OH to 1 mg lyophilized Aβ1-42 powder and immediately diluted in 1× phosphate-buffered saline (PBS) to the desired concentration. Hylite-555-Aβ42 was reconstituted in buffer containing 50 mmol/L Tris (pH 7.4) and 0.1% NH4OH to achieve 0.5 mg/mL and stored at −80°C (26).
Blood from the antecubital vein of healthy volunteers was drawn into citratephosphate-dextrose-adenine anticoagulant (citric acid anhydrous, 15 mmol/L; sodium citrate dihydrate, 86 mmol/L; monobasic sodium phosphate, 16 mmol/L; and dextrose, 130 mmol/L) under informed written consent, strictly as per the recommendations and as approved by the Institutional Ethical Committee of Banaras Hindu University. The study methodologies conformed to the standards set by the Declaration of Helsinki. Washed platelets were prepared from fresh human blood by differential centrifugation as described (31).
Cell Culture and Treatment
Human SH-SY5Y neuroblastoma cell line was cultured either in flasks or in 6- or 96-well plates in DMEM/F12, supplemented with 10% heat-inactivated fetal bovine serum, 1% MEM nonessential amino acids and 1% antibiotic-antimycotic solution at 37°C in a 95% humidified air-5% CO2 incubator. After 24 h, cells (which had reached ~80% confluence) were washed three times with a culture medium and thereafter incubated for 48 h in DMEM/F12 with 1% serum in the presence of Aβ1-42 or Aβ25-35. In the experiments designed to examine the protective effect of fibrinogen, cells were treated with either fibrinogen or BSA (as negative control) before exposure to Aβ1-42 or Aβ25-35. We performed the experiments using cells that had undergone fewer than 15 passages, and all studies were repeated several times with different batches of cells. Cells used for FACS analysis were grown in six-well cluster dishes, whereas those used for cell viability assays were grown in 96-well plates. Serum starvation and vehicle did not affect viability of control samples.
Platelet Aggregation and Dense Granule Secretion
Platelet-rich plasma (PRP) or washed human platelets (with or without fibrinogen) were stirred (1,200 rpm) at 37°C in an optical lumi-aggregometer (Chrono-log model 700-2, Wheecon Instruments) for 1 min, after which collagen (10 µg/mL) or different concentrations of Aβ25–35 were added, and transmittance was recorded. Aggregation was measured as percentage change in light transmission, where 100% refers to transmittance through blank solution for washed platelets or platelet-poor plasma for PRP (31). Secretion of adenine nucleotides from platelet-dense bodies was assessed in parallel with aggregation by measurement of luminescence using Chrono-lume luciferin-luciferase reagent following the manufacturer’s instructions (32).
Measurement of Platelet Intracellular Calcium
PRP was incubated with 2 µmol/L Fura-2/AM for 45 min at 37°C in the dark. Fura-2-loaded platelets were washed and resuspended in buffer B at 108 cells/mL. Fluorescence was recorded in 400-µL aliquots of platelet suspensions at 37°C under nonstirring conditions using a fluorescence spectrophotometer (Hitachi model F-2500). Excitation wavelengths were 340 and 380 nm, and emission wavelength was set at 510 nm. Changes in intracellular free calcium, [Ca2+]i, upon addition of Aβ to either control platelets or platelets preincubated with fibrinogen (2 mg/mL) were monitored from the fluorescence ratio (340/380) using the Intracellular Cation Measurement Program in FL Solutions software (31). Intracellular free calcium was calibrated according to the derivation of Grynkiewicz (33).
Surface expression of P-selectin. Washed human platelets (2 × 108 cells) were incubated at 37 °C for 10 min without stirring in the presence of thrombin (1 U/mL), Aβ25–35 (20 µmol/L) or fibrinogen (2 mg/mL) plus Aβ25-35 (20 µmol/L) and fixed for 30 min with 2% paraformaldehyde. Cells were washed twice in 1 × PBS, following which 5 µL fluorescein isothiocyanate (FITC)-labeled anti-CD62P antibody was added to each sample and incubated for 30 min in the dark at room temperature (RT). Cells were washed with 1 × PBS, resuspended in FACS sheath fluid and analyzed by flow cytometry as described above (31).
ROS measurement. Washed human platelets (2 × 108 cells), pretreated with either fibrinogen or BSA for 5 min, were incubated with either Aβ25–35 or Aβ1–42 for 15 min, followed by incubation with 2,7-dichlorodihydro fluorescent diacetate (H2DCFDA; final concentration 10 µM) for 30 min. Fluorescence was immediately measured using a flow cytometer (Becton Dickinson model FACSCalibur) with excitation wavelength of 488 nm and emission at 530 nm. Gated cells (n = 10,000) were analyzed for each sample.
For measurement of intracellular ROS in SH-SY5Y and N2a neuroblastoma cells, 105 cells were seeded per well in six-well plates in DMEM/F12. After 24 h of treatment with either fibrinogen or BSA (negative control), cells were detached with 1 mmol/L EDTA and washed with PBS. H2DCFDA was added to cells at a final concentration of 20 µmol/L and incubated for 30 min. Fluorescence was measured with flow cytometry as described above.
Mitochondrial Viability Measurement by MitoTracker Red Dye
For determination of mitochondrial viability, 105 cells were seeded per well in six-well plates in DMEM/F12. After 24 h of treatment with either fibrinogen or BSA, cells were detached with 1 mmol/L EDTA and washed twice with PBS, followed by incubation with MitoTracker dye (final concentration 500 nmol/L) for 45 min. Fluorescence was measured immediately using the flow cytometer in FL2 channel.
Platelet proteins were separated on 10% SDS-PAGE gels and electrophoretically transferred to polyvinylidene fluoride membrane using the TE 77 PWR semidry system (GE Healthcare). Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline (10 mmol/L Tris-HCl and 150 mmol/L NaCl, pH 8.0) containing 0.05% Tween-20 (TBST) for 1 h at RT. Blots were incubated overnight with respective primary antibodies (anti-MYPT1, 1:1000; anti-β-actin, 1:5000), followed by three washings with TBST for 5 min each. Membranes were then placed in horseradish peroxidase-labeled anti-IgG secondary antibodies appropriately diluted in blocking buffer or TBST for 1 h. Blots were similarly washed, and antibody binding was detected using the ECL detection kit. Images were acquired on a multispectral imaging system (BioSpectrum 800 Imaging System, UVP) and quantified using VisionWorks LS software (UVP).
Cell Viability Assay
Cells were plated at a density of 1 × 104 cells in 96-well plates and cultured for 24 h before treatment. Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described (34). Absorbance at 540 nm was measured using a microplate reader (BioTek Model Synergy H1). Viability of vehicle-treated control groups (not exposed to Aβ25–35) was defined as 100%.
For determination of cell viability using calcein/AM, 105 cells were seeded per well in a six-well plate in DMEM/F12. After 24 h of treatment, cells were detached using 1 mmol/L EDTA and washed with PBS. Calcein/AM was added to cells at a final concentration of 1 µg/mL, followed by incubation for 30 min. Fluorescence was analyzed immediately using the flow cytometer with excitation wavelength 488 nm and emission at 530 nm. Gated cells (n = 10,000) were analyzed for each sample.
Study of Aβ Interaction with Platelets and Neuronal Cells
Washed platelets were incubated with 5 µL of FITC-labeled anti-CD41a antibody and 5 µmol/L Hylite-555-Aβ42 for 15 min, with or without fibrinogen or BSA, washed with PBS and resus-pended in FACS sheath fluid. Fluorescence data were collected in FL1 and FL2 channel in the flow cytometer using four-quadrant logarithmic amplification of 10,000 events as described above. Untreated platelets served as control.
For confocal microscopy, platelets loaded with 1 µmol/L calcein/AM were treated with Hylite-555-Aβ42 in the presence of either fibrinogen or BSA or saline and were fixed overnight with 2% paraformaldehyde. Cells were examined under a Zeiss LSM 700 laser scanning confocal microscope with 10 × objective and 1 AU pinhole size. Images were acquired and analyzed using ZEN imaging software (Carl Zeiss) (26).
For the study of Aβ-neuronal cell interaction, SH-SY5Y cells were grown on glass chamber slides (Lab-Tek). After 24 h, cells were washed twice with culture medium, and fresh medium was added. Cells were incubated with fibrinogen, BSA or saline, followed by addition of Hylite-555-Aβ42. After another 24 h, cells were fixed with 2% paraformaldehyde, washed with PBS and visualized under a laser scanning confocal microscope (LSM 700, Zeiss) (26).
Clot Retraction Studies
Washed platelets (2 × 108 cells in 500 µL) were treated with either ADP (20 µmol/L) or Aβ25–35 (20 µmol/L) in the presence of calcium chloride (1 mmol/L) for 5 min at RT. Fibrinogen was added at a final concentration of 2 mg/mL either before or after addition of Aβ25–35. Atroxin (0.1 µg/mL) was added finally to initiate fibrinogen cleavage and clot formation. Contents were incubated at 37 °C. Clot retraction kinetics was observed, and images were captured at different time intervals and analyzed as described (35).
In Vitro Hemolysis Assay
In vitro hemolysis was carried out as described (31). To study the protective role of fibrinogen against Aβ-induced hemolysis, red blood cells (RBCs) were preincubated with fibrinogen (2 mg/mL) followed by exposure to varying concentrations of Aβ25–35 (5–20 µmol/L). RBCs suspended in deionized water or PBS served as positive and negative controls, respectively. Samples were incubated at 37°C for 1 h, followed by centrifugation at 10,000g for 10 min. Hemoglobin absorbance in the supernatant was measured at 540 nm in a microplate reader at 37°C. Percent hemolysis was calculated using the following equation:
All data are representative of at least three independent experiments. Two-tailed Student t test was used for evaluation of significance, and values of p < 0.05 were considered significant.
All supplementary materials are available online at www.molmed.org .
Aβ-Induced Platelet Activation and Clot Retraction Are Attenuated by Plasma Fibrinogen
We recently reported that active fragment of Aβ containing amino acid residues 25–35 (Aβ25–35; 20 µmol/L) induces aggregation of washed platelets (suspended in buffer) through RhoA-dependent modulation of myosin light chain phosphorylation and actomyosin organization (26). Intriguingly, we also found that Aβ25–35, even at concentrations as high as 50 µmol/L, failed completely to aggregate platelets suspended in plasma (Figure 1A). In contrast, physiological agonists such as collagen and ADP induced robust platelet aggregation under similar experimental conditions as expected. As Aβ has lately been shown to interact with fibrinogen (27), we subsequently studied the effect of fibrinogen added at physiological concentrations (36) to washed platelets in the presence of Aβ. Fibrinogen (2 mg/mL) significantly impaired platelet aggregation (p < 0.0001; tracing 3, Figure 1B), ATP release (p = 0.0021; tracing 3′, Figure 1B) and P-selectin exposure (p = 0.047; Figure 1E) induced by Aβ25–35 (20 µmol/L), while addition of BSA at similar concentrations to platelet suspension had no effect (tracings 4 and 4′, Figure 1B). Further, inhibition of Aβ25–35-induced platelet aggregation by fibrinogen was dose dependent (Figure 1C), with nearly total abrogation of aggregation at fibrinogen level 3 mg/mL. Fibrinogenmediated inhibition of platelet aggregation could be overcome by raising the concentration of Aβ25–35 (Figure 1D), which was suggestive of specific interaction between Aβ peptide and fibrinogen. Comparable results were obtained with full-length Aβ peptide. Aβ40-induced platelet aggregation and secretion was significantly inhibited by fibrinogen (Supplementary Figure S1).
We next studied whether fibrinogen can prevent retraction of the fibrin clot induced by Aβ-treated platelets. Platelets were stimulated with Aβ25-35, followed by addition of fibrinogen and atroxin. The latter is snake venom, which is known to elicit clot formation by cleavage of fibrinogen. Cytoskeletal contractility in platelets activated by Aβ25–35 evoked progressive compaction of the fibrin clot for up to 60 min. Strikingly, retraction of the clot was precluded when platelets were incubated with fibrinogen before addition of Aβ25–35 (Figure 1F). Pretreatment with fibrinogen, however, had no inhibitory effect on retraction of the clot when Aβ was substituted with ADP.
Agonist stimulation of platelets is known to be associated with increases in cytosolic Ca+2 and reactive oxygen species (ROS). In agreement with earlier reports (37,38), Aβ25–35 brought about a sharp rise in both intracellular ROS (Figure 2A) and Ca+2 (Figure 2B). The rise was almost completely abrogated by pretreatment of cells with fibrinogen (2 mg/mL; p = 0.0024). We have recently demonstrated that the stimulatory effect of Aβ on platelets is mediated through the RhoA-MYPT1-myosin light chain (MLC) axis (26). As expected, Aβ40-aggregated platelets were associated with enhanced phosphorylation of MYPT1. Fibrinogen (3 mg/mL), too, abolished Aβ-induced RhoA signaling in these platelets, as evidenced by the lack of rise in the level of phospho-MYPT1 upon Aβ40 treatment (Figure 2C, D).
We next asked whether the effect of Aβ25–35 on RBCs, the other abundant cell type in blood, too, was precluded by fibrinogen. As expected, Aβ25–35 induced lysis of red blood cells suspended in isotonic buffer (39), which was absolutely mitigated in the presence of 2 mg/mL fibrinogen (p < 0.0001; Supplementary Figure S2).
Fibrinogen Prevents Interaction of Aβ with Platelets and Neuronal Cells
We employed fluorescently labeled Aβ peptide (Hylite-555-Aβ42) to explore Aβ-platelet interaction in the presence or absence of fibrinogen. As we have demonstrated earlier (26), platelets incubated with Hylite-555-Aβ42 exhibited gains in FL2 fluorescence in flow cytometric analysis, indicative of association of Aβ with platelets. The percentage of FL2-positve events within platelet gate was significantly reduced when cells were pretreated with either fibrinogen (2 mg/mL; p = 0.02; Figure 3D) or plasma (p = 0.016; Figure 3F) but not with BSA (2 mg/mL; control; Figure 3E).
In concurrence, confocal microscopy of platelets treated with Hylite-555-Aβ42 revealed intracellular accumulation of Aβ, which was significantly reduced in the presence of fibrinogen, and Hylite-555-Aβ42 fluorescence was found to be scattered/dispersed extracellularly (Figure 4). Pretreatment with saline or BSA, in place of fibrinogen, did not prevent Aβ internalization.
Next, we explored the influence of fibrinogen on the association between Hylite-555-labeled Aβ42 and SH-SY5Y neuroblastoma cells by confocal microscopy (40). Consistent with the above observations, pretreatment with fibrinogen but not BSA brought about significant reductions in Aβ-neuronal cell interaction (p < 0.0001; Figure 5).
As fibrinogen attenuated Aβ-induced platelet activation and hemolysis, we hypothesized that it could similarly mitigate neurotoxicity of Aβ. Aβ25-35 brought about a dose-dependent decline in viability of SH-SY5Y neuroblastoma cells as estimated by MTT assay (41,42). Fibrinogen (2 mg/mL) remarkably ameliorated the decrease in cell viability at all concentrations of Aβ25–35 studied (Supplementary Figure S3). The neurotoxicity of Aβ has been attributed to mitochondrial dysfunction (7) and oxidative stress (10). Aβ25-35 (20 µmol/L) triggered a drop in neuronal cell mitochondrial transmembrane potential and a rise in intracellular ROS levels, which were abrogated by 23% and 50%, respectively, in the presence of fibrinogen (2 mg/mL; Supplementary Figure S3).
This study demonstrates that fibrinogen attenuates platelet activation and cytotoxicity induced by active fragment of Aβ (Aβ25–35) by preventing Aβ (Aβ42) interaction with cells. We had recently reported that Aβ provokes strong stimulation of human platelets through RhoA-dependent modulation of MLC phosphorylation and actomyosin organization (26). This observation was supported by the presence of “preactivated” platelets in mouse models of AD (43). Platelets preincubated with Aβ, too, exhibited enhanced adhesion to injured carotid artery in mice (37). Taken together, the above reports are suggestive of Aβ-platelet interaction resulting in a prothrombotic phenotype that contributes to CAA associated with AD.
Intriguingly, we found that Aβ25–35, unlike physiological agonists such as collagen and ADP, failed to induce aggregation of platelets suspended in plasma. As plasma fibrinogen has been reported to be one of the binding partners for Aβ (27), we evaluated the influence of fibrinogen on Aβ-induced platelet aggregation. Fibrinogen brought about dose-dependent declines in aggregatory response elicited by Aβ25–35 (20 µmol/L), with nearly total abrogation of aggregation at fibrinogen concentrations ≥2 mg/mL (normal plasma fibrinogen level being 2–4 mg/mL), which was reversed by Aβ25–35 added in increasing doses. Fibrinogen attenuated Aβ-induced platelet responses such as exocytosis of granule contents and rise in cytosolic Ca+2 and ROS. Aβ-induced RhoA signaling was also abolished by fibrinogen. Consistent with these findings, intracellular accumulation of exogenous Aβ, as was reported earlier (26), was found by confocal microscopy to be dramatically impeded in the presence of fibrinogen, although the association of Aβ with platelets was only moderately diminished as evidenced by flow cytometry. The majority of platelet-associated Aβ remained extracellular in the presence of fibrinogen. Thus, inhibition of Aβ-induced platelet responses by fibrinogen could possibly be attributable to lack of Aβ internalization.
Platelets contribute to >90% amyloid precursor protein in circulation (44), which, upon proteolytic cleavage by β- and γ-secretases, yields Aβ40 (45). Despite low plasma levels, high local concentrations of Aβ are achieved (28) at the site of thrombus formation owing to release from stimulated platelets (46,47) and at the sites of CAA (48) or atherosclerotic plaques (49,50), which can initiate vicious cycles of platelet stimulation and Aβ release and potentially lead to massive thrombosis. Based on observations presented in this study, it is tempting to speculate that fibrinogen acts as a physiological “shield” to preclude Aβ-induced activation of platelets, thus keeping the prothrombotic attributes of amyloid peptide strictly under check and providing steady protection against thrombotic vascular occlusion. It has, however, been reported that fibrin clots are rendered resistant to lysis following interaction with amyloid peptide (28–30). Thus, even as the probability of Aβ-induced platelet activation is minimized in the presence of fibrinogen, Aβ would prolong the half-life of an eventual clot. This hypothesis is consistent with our previous findings, that although Aβ was not thrombogenic on its own, it exacerbated pulmonary thromboembolism induced by collagen-epinephrine in a mouse model (26).
Next, we asked whether fibrinogen could, too, protect neuronal cells from Aβ-mediated toxicity similar to platelets. In fact, preincubation with fibrinogen did significantly impair the association of Aβ peptide with neurons and reversed the drop in neuronal cell viability and mitochondrial transmembrane potential induced in the presence of Aβ. Although fibrinogen cannot normally gain access to the central nervous system, altered blood-brain barrier permeability associated with AD can allow extravasation of plasma proteins, including fibrinogen, into brain parenchyma (51). Further, there is increasing evidence for a crucial role of dynamic exchange of Aβ between brain and plasma during AD pathogenesis (52). Here we show that fibrinogen can possibly serve as a peripheral sink sequestering Aβ in plasma and minimizing Aβ-mediated toxicity.
It has recently been demonstrated that fibrin(ogen) deposits in cerebral vasculature contribute to the pathogenesis of AD (29,30,53). This was attributed to resistance of fibrin clots to degradation upon interaction with Aβ, which in turn would lead to reduced cerebral blood flow. There are also reports to suggest that fibrin deposited in AD brain could promote vascular pathology, which is dependent on fibrin(ogen)’s ability to activate microglial CD11b receptors (51). Thus, our findings, when considered in the context of the above reports, suggest that fibrinogen has dualistic role in the pathogenesis of prothrombotic phenotype as well as AD.
We conclude that fibrinogen circulating peripherally in plasma sequesters Aβ, serving as a physiological deterrent to Aβ-induced thrombogenecity and platelet activation. Peptides or small molecules that could similarly sequester Aβ and prevent its interaction with cells can be potentially therapeutic in AD and CAA.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
Selkoe DJ. (2001) Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 81:741–766.
Masters CL, et al. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82:4245–4249.
Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 85:4051–4055.
Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J. Biol. Chem. 285:13107–13120.
Hardy JA, Higgins GA. (1992) Alzheimer’s disease: The amyloid cascade hypothesis. Science. 256:184–185.
Sakono M, Zako T. (2010) Amyloid oligomers: Formation and toxicity of Abeta oligomers. FEBS J. 277:1348–1358.
Pagani L, Eckert A. (2011) Amyloid-beta interaction with mitochondria. Int. J. Alzheimers Dis. 2011:925050.
Mattson MP, Chan SL. (2001) Dysregulation of cellular calcium homeostasis in Alzheimer’s disease: Bad genes and bad habits. J. Mol. Neurosci. 17:205–224.
Berridge MJ. (2014) Calcium regulation of neural rhythms, memory and Alzheimer’s disease. J. Physiol. 592:281–293.
Cai Z, Zhao B, Ratka A. (2011) Oxidative stress and beta-amyloid protein in Alzheimer’s disease. Neuromolecular Med. 13:223–250.
Hynd MR, Scott HL, Dodd PR. (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem. Int. 45:583–595.
Kudo W, et al. (2012) Inhibition of Bax protects neuronal cells from oligomeric Aβ neurotoxicity. Cell Death Dis. 3:e309.
Sanphui P, Biswas SC. (2013) FoxO3a is activated and executes neuron death via Bim in response to beta-amyloid. Cell Death Dis. 4:e625.
Townsend M, Mehta T, Selkoe DJ. (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282:33305–33312.
Magdesian MH, et al. (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem. 283:9359–9368.
Fryer JD, et al. (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25:2803–2810.
Vinters HV. (1987) Cerebral amyloid angiopathy. A critical review. Stroke. 18:311–324.
Hsu MJ, et al. (2007) Apoptosis signal-regulating kinase 1 in amyloid beta peptide-induced cerebral endothelial cell apoptosis. J. Neurosci. 27:5719–5729.
Davis J, Cribbs DH, Cotman CW, Van Nostrand WE. (1999) Pathogenic amyloid beta-protein induces apoptosis in cultured human cerebrovascular smooth muscle cells. Amyloid. 6:157–164.
de la Torre JC. (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3:184–190.
Hines P. (2013) Amyloid binding partners. Sci. Signal. 6:ec230.
De Felice FG, et al. (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282:11590–11601.
Wang HY, et al. (2000) Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J. Biol. Chem. 275:5626–5632.
Coulson EJ. (2006) Does the p75 neurotrophin receptor mediate Aβ-induced toxicity in Alzheimer’s disease? J. Neurochem. 98:654–660.
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 457:1128–1132.
Sonkar VK, Kulkarni PP, Dash D. (2014) Amyloid beta peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization. FASEB J. 28:1819–1829.
Ahn HJ, et al. (2010) Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. U. S. A. 107:21812–21817.
Zamolodchikov D, Strickland S. (2012) Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood. 119:3342–3351.
Cortes-Canteli M, et al. (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: A possible contributing factor to Alzheimer’s disease. Neuron. 66:695–709.
Ahn HJ, et al. (2014) A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J. Exp. Med. 211:1049–1062.
Singh SK, et al. (2012) Amine-modified graphene: Thrombo-protective safer alternative to graphene oxide for biomedical applications. ACS Nano. 6:2731–2740.
Singh SK, et al. (2011) Thrombus inducing property of atomically thin graphene oxide sheets. ACS Nano. 5:4987–4996.
Grynkiewicz G, Poenie M, Tsien RY. (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440–3450.
Soundararajan R, et al. (2008) Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells in vitro against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. J. Biol. Chem. 283:2231–2245.
Shrivastava S, et al. (2009) Characterization of antiplatelet properties of silver nanoparticles. ACS Nano. 3:1357–1364.
Comeglio P, et al. (1996) Blood clotting activation during normal pregnancy. Thromb. Res. 84:199–202.
Gowert NS, et al. (2014) Blood platelets in the progression of Alzheimer’s disease. PLoS One. 9:e90523.
Canobbio I, et al. (2014) Amyloid beta-peptide-dependent activation of human platelets: Essential role for Ca2+ and ADP in aggregation and thrombus formation. Biochem. J. 462:513–523.
Nakagawa K, et al. (2011) Amyloid beta-induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett. 585:1249–1254.
Hu X, et al. (2009) Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. U. S. A. 106:20324–20329.
Behl C, Davis JB, Lesley R, Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:817–827.
Sagara Y, Dargusch R, Klier FG, Schubert D, Behl C. (1996) Increased antioxidant enzyme activity in amyloid beta protein-resistant cells. J. Neurosci. 16:497–505.
Jarre A, et al. (2014) Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell. Signal. 26:2040–2050.
Bush AI, et al. (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J. Biol. Chem. 265:15977–15983.
Vassar R, et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:735–741.
Skovronsky DM, Lee VM, Pratico D. (2001) Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J. Biol. Chem. 276:17036–17043.
Smith CC. (1997) Stimulated release of the beta-amyloid protein of Alzheimer’s disease by normal human platelets. Neurosci. Lett. 235:157–159.
Deane R, Wu Z, Zlokovic BV. (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 35:2628–2631.
Roher AE, et al. (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement. 5:18–29.
Canobbio I, et al. (2013) Immobilized amyloid Aβ peptides support platelet adhesion and activation. FEBS Lett. 587:2606–2611.
Ryu JK, McLarnon JG. (2009) A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J. Cell. Mol. Med. 13:2911–2925.
Sagare AP, Bell RD, Zlokovic BV. (2013) Neuro-ascular defects and faulty amyloid-β vascular clearance in Alzheimer’s disease. J. Alzheimers Dis. 33(Suppl 1):S87–100.
Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer’s disease brain promotes neuronal degeneration. Neurobiol. Aging. 36:608–617.
This research was supported by grants received by D Dash from the Department of Science and Technology (DST), Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR) and the Council of Scientific and Industrial Research (CSIR), Government of India. D Dash thankfully acknowledges DST-FIST program and Tata Innovation Fellowship grant received from DBT.
Electronic Supplementary Material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)
About this article
Cite this article
Sonkar, V.K., Kulkarni, P.P., Chaurasia, S.N. et al. Plasma Fibrinogen Is a Natural Deterrent to Amyloid β-Induced Platelet Activation and Neuronal Toxicity. Mol Med 22, 224–232 (2016). https://doi.org/10.2119/molmed.2016.00003
- Washed Human Platelets
- Dose-dependent Decline
- Clot Retraction
- Ethylene Diaminetetraacetic Acid (EDTA)